111, Inc. Form 6-K Summary
Business Context and Reporting Period
111, Inc., a China-based healthcare and pharmaceutical e-commerce company, filed this Report of Foreign Issuer for March 2022. The filing was dated March 1, 2022.
Material Corporate Change
The company terminated the contractual arrangements between its PRC subsidiary, 1 Pharmacy Technology (Shanghai) Co., Ltd., and its former variable interest entities:
- Guangdong Yihao Pharmacy Co., Ltd.
- Guangdong Yihao Pharmaceutical Chain Co., Ltd.
- Shanghai Yaowang E-Commerce Co., Ltd.
The arrangements with the entities and their respective shareholders were terminated. The company stated that it consequently has direct equity control of these entities.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, balance sheet, or other financial metrics.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance or operational outlook is provided. The change in ownership and control structure may affect the company’s consolidation, accounting presentation, corporate governance, and regulatory risk profile, but the filing does not describe the financial or legal effects of the restructuring.
Key Facts to Verify
- Whether the entities are now directly consolidated in the company’s financial statements.
- The effective date and legal documentation for termination of the contractual arrangements.
- The percentage of direct equity ownership obtained in each entity.
- Any resulting changes to accounting treatment, related-party disclosures, or historical financial comparability.
- Any regulatory, tax, shareholder, or operating consequences not described in this Form 6-K.